Saturday, November 30, 2019

FDA Approval of Xofluza (baloxavir marboxil) for High Risk of Developing Influenza-Related Complications

›
 Genentech, a member of the Roche Group,  announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug ...
Friday, November 29, 2019

FDA Approves Second Drug, Vyleesi, to Help Women With Low Libido

›
In continuation of my update on bremelanotide The U.S. Food and Drug Administration on Friday gave its approval to Vyleesi, the secon...
Thursday, November 28, 2019

FDA Approves Secuado (asenapine) Transdermal System for the Treatment of Adults with Schizophrenia

›
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced the U.S. Food and Drug Admin...
Wednesday, November 27, 2019

FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters

›
   UCB announced   that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company’s newest a...
Tuesday, October 15, 2019

Is Green Tea a Fad or a Real Health Boost?

›
In continuation of my updates on Green tea Green tea is a popular health trend, with many people sipping in hopes of deriving benefi...
Saturday, October 12, 2019

Coffee Might Be Your Go-to Brew for Weight Loss

›
In continuation of my update on coffee Could America's favorite morning drink also help fight one of its biggest health issues, ...
Friday, October 11, 2019

AbbVie Announces US FDA Approval of Venclexta (venetoclax) as a Chemotherapy-Free Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia Patients

›
In continuation of my update on  Venclexta (venetoclax) AbbVie a research-based global biopharmaceutical  company,  announced th...
Thursday, October 10, 2019

FDA Approves Victoza (liraglutide) for the Treatment of Pediatric Patients 10 Years or Older with Type 2 Diabetes

›
In continuation of my update on Victoza (liraglutide) The U.S. Food and Drug Administration   approved Victoza (liraglutide) injection...
Wednesday, October 9, 2019

FDA Approves Symdeko (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

›
In continuation of my update on tezacafto     Tezacaftor                                                                           ...